Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer (NCT04093167)
A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.
Who can join: Review the eligibility criteria below.
Location: The University of Chicago Medical Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- The University of Chicago Medical Center — Chicago, Illinois
- The Sidney Kimmel Comprehensive Cancer Centre — Baltimore, Maryland
- Cross Cancer Institute — Edmonton, Alberta
- BCCA - Vancouver — Vancouver, British Columbia
- Health Sciences North — Greater Sudbury, Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- Algoma District Cancer Program — Sault Ste. Marie, Ontario
- University Health Network — Toronto, Ontario
- The Jewish General Hospital — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer
- Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
- Early Detection of Lung Cancer — Nashville, Tennessee
- Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
- Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
- Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
- Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts
Explore by condition: All Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.